Nigeria adopted dolutegravir (DTG) as part of first line (1L) antiretroviral therapy (ART) in 2017. However, there is limited documented experience using DTG in sub-Saharan Africa. Our study assessed DTG acceptability from the patient’s perspective as well as treatment outcomes at 3 high-volume facilities in Nigeria. This is a mixed method prospective cohort study with 12 months of follow-up between July 2017 and January 2019. Patients who had intolerance or contraindications to non-nucleoside reverse-transcriptase inhibitors were included. Patient acceptability was assessed through one-on-one interviews at 2, 6, and 12 months following DTG initiation. ART-experienced participants were asked about side effects and regimen preference compared to their previous regimen. Viral load (VL) and CD4+ cell count tests were assessed according to the national schedule. Data were analysed in MS Excel and SAS 9.4. A total of 271 participants were enrolled on the study, the median age of participants was 45 years, 62% were female. 229 (206 ART-experienced, 23 ART-naive) of enrolled participants were interviewed at 12 months. 99.5% of ART-experienced study participants preferred DTG to their previous regimen. 32% of particpants reported at least one side effect. “Increase in appetite” was most frequently reported (15%), followed by insomnia (10%) and bad dreams (10%). Average adherence as measured by drug pick-up was 99% and 3% reported a missed dose in the 3 days preceding their interview. Among participants with VL results (n = 199), 99% were virally suppressed (

Table S1: Gene Set Enrichment Analysis (GSEA) of the oncogenic signature gene sets (MSigDB C6 gene set) enriched in Tex versus Teff cell clusters. RNA-seq data are mined from GSE89307, GSE84820, and GSE86881. Refer to first tab of excel sheet for detailed description of column headings in subsequent data tab. Table S2: qPCR, shRNA and sgRNA oligonucleotide sequences. 5’ to 3’ oligonucleotide sequences used for qPCR, CRISPR-Cas9 mediated knockout, and shRNA-mediated knockdown. Q denotes primers used for qPCR, and F and R denote forward and reverse primers, respectively. Table S3: Differential gene expression analysis from RNA-seq of adoptively transferred Keap1-/- versus WT P14 cells, isolated 7 days post LCMV Armstrong infection. Refer to first tab of excel sheet for detailed description of column headings in subsequent data tab. Table S4: C2, C5, C6, C7, NFE2L2.v2 and H Gene set enrichment analysis (GSEA) from RNA-seq of Keap1-/- versus WT P14+ CD8+ T cells upon LCMV Armstrong infection. A Positive or negative normalized enrichment score (NES) indicates a gene set enrichment in Keap1-/- cells or WT cells, respectively. Refer to first tab of excel sheet for detailed description of column headings in subsequent data tabs. Table S5: Differential gene expression analysis from RNA-seq of in vitro cultured CD8+ T cells with variable expression of PTGIR, treated with vehicle or iloprost. Refer to first tab of excel sheet for detailed description of column headings in subsequent data tabs. Table S6: Pathway analysis from RNA-seq of in vitro cultured CD8+ T cells with variable expression of PTGIR, treated with vehicle or iloprost. Refer to first tab of excel sheet for detailed description of column headings in subsequent data tabs. Liver annotated blots: Original western blot (labelled) for liver cell western blots show in Figure 1D HO1_LAMINB1_Tcells- Original western blot (labelled) for HO-1 and LAMIN B1 T cell western blots show in Figure 1D. KEAP1_Tcells- Original western blot (labelled) for KEAP1 T cell western blots show in Figure 1D. NQO1_Tcells- Original western blot (labelled) for KEAP1 T cell western blots show in Figure 1D.

pone.0284767.t001 - High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria

Excel file containing compiled primary experimental data subjected to statistical analyses.

Nigeria adopted dolutegravir (DTG) as part of first line (1L) antiretroviral therapy (ART) in 2017. However, there is limited documented experience using DTG in sub-Saharan Africa. Our study assessed DTG acceptability from the patient’s perspective as well as treatment outcomes at 3 high-volume facilities in Nigeria. This is a mixed method prospective cohort study with 12 months of follow-up between July 2017 and January 2019. Patients who had intolerance or contraindications to non-nucleoside reverse-transcriptase inhibitors were included. Patient acceptability was assessed through one-on-one interviews at 2, 6, and 12 months following DTG initiation. ART-experienced participants were asked about side effects and regimen preference compared to their previous regimen. Viral load (VL) and CD4+ cell count tests were assessed according to the national schedule. Data were analysed in MS Excel and SAS 9.4. A total of 271 participants were enrolled on the study, the median age of participants was 45 years, 62% were female. 229 (206 ART-experienced, 23 ART-naive) of enrolled participants were interviewed at 12 months. 99.5% of ART-experienced study participants preferred DTG to their previous regimen. 32% of particpants reported at least one side effect. “Increase in appetite” was most frequently reported (15%), followed by insomnia (10%) and bad dreams (10%). Average adherence as measured by drug pick-up was 99% and 3% reported a missed dose in the 3 days preceding their interview. Among participants with VL results (n = 199), 99% were virally suppressed (

Summary statistics of the CD4+ cell count disaggregated by ART status.

Summary statistics of plasma HIV-1 RNA viral load results.